Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Some blind vision loss cases have been linked to the use of weight-loss jabs, including Ozempic, so caution is recommended by ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.